NASDAQ:VIR

Vir Biotechnology (VIR) Stock Forecast, Price & News

$25.43

-0.45 (-1.74%)

(As of 06/9/2023 ET)

Compare

Today's Range: $25.34
▼
$26.10
50-Day Range: $23.20
▼
$27.29
52-Week Range: $18.05
▼
$31.78

Volume: 597,500 shs
Average Volume: 762,652 shs
Market Capitalization: $3.41 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $49.75

Vir Biotechnology MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 95.6% Upside
$49.75 Price Target
Short Interest: Bearish
6.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 14 Articles This Week
Insider Trading: Selling Shares
$23.03 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.80) to ($4.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

693rd out of 987 stocks

Biological Products, Except Diagnostic Industry

114th out of 154 stocks

3.4

Analyst's Opinion

Consensus Rating
Vir Biotechnology has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $49.75, Vir Biotechnology has a forecasted upside of 95.6% from its current price of $25.43.
Amount of Analyst Coverage
Vir Biotechnology has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.00% of the float of Vir Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Vir Biotechnology has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Vir Biotechnology has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vir Biotechnology does not currently pay a dividend.
Dividend Growth
Vir Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VIR.

1.7

News and Social Media Coverage

News Sentiment
Vir Biotechnology has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Vir Biotechnology this week, compared to 6 articles on an average week.
Search Interest
Only 2 people have searched for VIR on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,027,074.00 in company stock.
Percentage Held by Insiders
18.10% of the stock of Vir Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.97% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vir Biotechnology are expected to decrease in the coming year, from ($3.80) to ($4.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vir Biotechnology is -23.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vir Biotechnology is -23.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vir Biotechnology has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Stock News Headlines

June 10, 2023 | americanbankingnews.com

Phillip Pang Sells 5,000 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 9, 2023 | americanbankingnews.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells 34,365 Shares of Stock

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

June 8, 2023 | americanbankingnews.com

Endurance (Cayman) Ltd Svf Sells 5,197 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) Stock

June 7, 2023 | benzinga.com

Vir Biotechnology 10% Owner Trades Company's Stock

June 7, 2023 | finance.yahoo.com

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B and D Data Accepted for Presentation at EASL™ Congress 2023

June 5, 2023 | finance.yahoo.com

Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

June 5, 2023 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Insider Sells $64,175.00 in Stock

June 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

June 3, 2023 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $26.67

May 28, 2023 | americanbankingnews.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,729,641.60 in Stock

May 27, 2023 | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down Following Insider Selling

May 26, 2023 | fool.com

Vir Biotechnology (NASDAQ: VIR)

May 26, 2023 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,326,102.38 in Stock

May 26, 2023 | americanbankingnews.com

Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,363,565.12 in Stock

May 25, 2023 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Analysts

May 24, 2023 | americanbankingnews.com

Contrasting Vir Biotechnology (NASDAQ:VIR) & BioCardia (NASDAQ:BCDA)

May 18, 2023 | seekingalpha.com

Vir Biotechnology (VIR) Investor Presentation - Slideshow

May 17, 2023 | finance.yahoo.com

Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders

May 15, 2023 | finance.yahoo.com

Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 50% of the company

May 15, 2023 | finance.yahoo.com

Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer

May 13, 2023 | americanbankingnews.com

HC Wainwright Weighs in on Vir Biotechnology, Inc.'s Q3 2023 Earnings (NASDAQ:VIR)

May 11, 2023 | finance.yahoo.com

Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI

May 9, 2023 | bizjournals.com

Retired Vir CEO George Scangos lands on two boards with links to old company

May 9, 2023 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) to Post Q4 2023 Earnings of $1.04 Per Share, SVB Leerink Forecasts

May 8, 2023 | americanbankingnews.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $2,134,523.74 in Stock

May 8, 2023 | americanbankingnews.com

SVB Securities Lowers Vir Biotechnology (NASDAQ:VIR) Price Target to $42.00

See More Headlines

VIR Price History

30 days | 90 days | 365 days | Advanced Chart

VIR Company Calendar

Last Earnings: 5/04/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VIR
CUSIP: N/A
CIK: 1706431
Web: www.vir.bio
Phone: 415-906-4324
Fax: N/A
Employees: 444
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $49.75
High Stock Price Forecast: $100.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +95.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $515.84 million
Net Margins: N/A
Pretax Margin: -69.64%
Return on Equity: -7.05%
Return on Assets: -5.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.86
Quick Ratio: 4.86

Sales & Book Value

Annual Sales: $1.62 billion
Price / Sales: 2.11
Cash Flow: $3.79 per share
Price / Cash Flow: 6.71
Book Value: $15.61 per share
Price / Book: 1.63

Miscellaneous

Outstanding Shares: 134,000,000
Free Float: 109,746,000
Market Cap: $3.41 billion
Optionable: Optionable
Beta: 0.26

Key Executives

Dr. George A. Scangos Ph.D. (Age 75)
Pres, CEO & Director
Comp: $1.07M

Mr. Howard Horn (Age 45)
Exec. VP, CFO & Sec.
Comp: $732.41k

Dr. Ann M. Hanly Ph.D. (Age 53)
Exec. VP & Chief Technology Officer
Comp: $922.22k

Dr. Phillip Pang M.D. (Age 48)
Ph.D., Exec. VP, Chief Medical Officer & Interim Head of Research
Comp: $780.46k

Dr. Klaus Frueh Ph.D. (Age 63)
Co-Founder & Scientific Advisor

Dr. Lawrence Corey M.D.
Co-Founder & Scientific Advisor

Dr. Louis J. Picker M.D.
Co-Founder & Scientific Advisor

Ms. Johanna Friedl-Naderer (Age 55)
Exec. VP & COO

Mr. Steven J. Rice (Age 63)
Exec. VP & Chief Admin. Officer

Ms. Heather Rowe Armstrong
VP of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VIR Stock - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VIR shares.
View VIR analyst ratings or view top-rated stocks.
What is Vir Biotechnology's stock price forecast for 2023?: 6 Wall Street research analysts have issued 12 month price targets for Vir Biotechnology's shares. Their VIR share price forecasts range from $27.00 to $100.00. On average, they expect the company's stock price to reach $49.75 in the next twelve months. This suggests a possible upside of 95.6% from the stock's current price.
View analysts price targets for VIR or view top-rated stocks among Wall Street analysts.
How have VIR shares performed in 2023?: Vir Biotechnology's stock was trading at $25.31 at the start of the year. Since then, VIR shares have increased by 0.5% and is now trading at $25.43.
View the best growth stocks for 2023 here.
When is Vir Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our VIR earnings forecast.
How were Vir Biotechnology's earnings last quarter?: Vir Biotechnology, Inc. (NASDAQ:VIR) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.20. The company had revenue of $63 million for the quarter, compared to analysts' expectations of $50.10 million. The business's revenue was down 94.9% compared to the same quarter last year. During the same period last year, the business earned $3.93 earnings per share.
What ETFs hold Vir Biotechnology's stock?: ETFs with the largest weight of Vir Biotechnology (NASDAQ:VIR) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Hartford Multifactor Small Cap ETF (ROSC), SPDR S&P Biotech ETF (XBI) and ETC 6 Meridian Small Cap Equity ETF (SIXS).
What is George Scangos' approval rating as Vir Biotechnology's CEO?: 7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?: (VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO.
What is Vir Biotechnology's stock symbol?: Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."
Who are Vir Biotechnology's major shareholders?: Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (13.67%), BlackRock Inc. (10.42%), Temasek Holdings Private Ltd (4.34%), State Street Corp (4.02%), Baillie Gifford & Co. (2.98%) and Geode Capital Management LLC (1.14%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.
How do I buy shares of Vir Biotechnology?: Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vir Biotechnology's stock price today?: One share of VIR stock can currently be purchased for approximately $25.43.
How much money does Vir Biotechnology make?: Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $3.41 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.10) on an earnings per share basis.
How many employees does Vir Biotechnology have?: The company employs 444 workers across the globe.
How can I contact Vir Biotechnology?: Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.

This page (NASDAQ:VIR) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial